Item request has been placed!
×
Item request cannot be made.
×

Processing Request
Refining precision prognostics in multiple myeloma: loss of miR-221/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcome
Item request has been placed!
×
Item request cannot be made.
×

Processing Request
- Author(s): Soureas, Konstantinos Malandrakis, Panagiotis Papadimitriou, Maria-Alexandra Minopoulos, Christos Ntanasis-Stathopoulos, Ioannis Liacos, Christine-Ivy Gavriatopoulou, Maria Kastritis, Efstathios Dimopoulos, Meletios-Athanasios Scorilas, Andreas Avgeris, Margaritis Terpos, Evangelos
- Document Type:
Electronic Resource
- Online Access:
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3498196
- Additional Information
- Publisher Information:
2025-01-01
- Abstract:
The persistence of high relapse rates and therapy resistance continues to challenge the effective management of multiple myeloma (MM). The identification of novel MM-specific molecular markers could ameliorate risk-stratification tools and accurately identify high-risk patients towards personalized prognosis and therapy. miRNA-seq analysis of CD138+ plasma cells (n = 24) unveiled miR-221-3p and miR-222-3p (miR-221/222 cluster) as the most downregulated miRNAs in R-ISS III compared to R-ISS I/II patients. Subsequently, miR-221/222 levels were quantified by RT-qPCR in CD138+ plasma cells of our screening cohort (n = 141), assessing patients’ mortality and disease progression as clinical endpoints. Internal validation was performed by bootstrap analysis, while clinical benefit was estimated by decision curve analysis. Kryukov et al. (n = 149) and Aass et al. (n = 86) served as institutional-independent validation cohorts. Loss of miR-221/222 cluster was strongly associated with patients’ short-term progression and poor overall survival, which was confirmed by Kryukov et al. and Aass et al. validation cohorts. Intriguingly, miR-221/222-fitted multivariate models offered superior risk-stratification within R-ISS staging and risk-based cytogenetics. Moreover, miR-221/222 loss could effectively discriminate optimal 1st-line treatment responders with inferior treatment outcome. Our study identified the loss of miR-221/222 cluster as a powerful independent predictor of patients’ post-treatment progression, ameliorating prognosis and supporting precision medicine in MM. (Figure presented.) © The Author(s) 2025.
- Subject Terms:
- Availability:
Open access content. Open access content
- Note:
English
- Other Numbers:
GRNKU oai:lib.uoa.gr:uoadl:3498196
uoadl:3498196
1523435131
- Contributing Source:
NATIONAL & KAPODISTRIAN UNIV OF ATHENS
From OAIster®, provided by the OCLC Cooperative.
- Accession Number:
edsoai.on1523435131
HoldingsOnline
No Comments.